Breast cancer affects one in eight women around the world. Seventy five percent of these patients have tumors that are estrogen receptor positive and as a consequence receive endocrine therapy. However,about one third...Breast cancer affects one in eight women around the world. Seventy five percent of these patients have tumors that are estrogen receptor positive and as a consequence receive endocrine therapy. However,about one third eventually develop resistance and cancer reappears. In the last decade our vision of cancer has evolved to consider it more of a tissuerelated disease than a cell-centered one. This editorial argues that we are only starting to understand the role the tumor microenvironment plays in therapy resistance in breast cancer. The development of new therapeutic strategies that target the microenvironment will come when we clearly understand this extremely complicated scenario. As such,and as a scientific community,we have extremely challenging work ahead. We share our views regarding these matters.展开更多
基金Supported by The Ministerio de CienciaTecnología e Inno-vación Productiva+1 种基金No.PICT2008-0325by CONICET
文摘Breast cancer affects one in eight women around the world. Seventy five percent of these patients have tumors that are estrogen receptor positive and as a consequence receive endocrine therapy. However,about one third eventually develop resistance and cancer reappears. In the last decade our vision of cancer has evolved to consider it more of a tissuerelated disease than a cell-centered one. This editorial argues that we are only starting to understand the role the tumor microenvironment plays in therapy resistance in breast cancer. The development of new therapeutic strategies that target the microenvironment will come when we clearly understand this extremely complicated scenario. As such,and as a scientific community,we have extremely challenging work ahead. We share our views regarding these matters.
